SCHEMBL2436071

SCHEMBL2436071

CNc1ccc(C(=O)O)c(OCCCNC(C)=O)c1

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.50
USP2 O75604 1/20 0.48
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.48
MAPK1 P28482 1/20 0.48
HSD17B10 Q99714 1/20 0.48
MTNR1B P49286 6/20 0.45
MTNR1A P48039 6/20 0.45
RAB9A P51151 1/20 0.44
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
FOLH1 Q04609 4/20 0.42
SYK P43405 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2433726 0.86 ALDH1A1 (0.41) MTNR1BMTNR1AALDH1A1HPGDSYK
SCHEMBL2434386 0.83 ALDH1A1 (0.54) L3MBTL1USP2ALOX15TSHRMAPK1
SCHEMBL2433961 0.82 MELK (0.47) HSD17B10RAB9AKDM4EALDH1A1TDP1
SCHEMBL2434310 0.82 ACHE (0.44) L3MBTL1USP2ALOX15TSHRMAPK1
SCHEMBL14354369 0.82 SYK (0.43) L3MBTL1USP2ALOX15TSHRMAPK1
SCHEMBL28489272 0.77 TDP1 (0.60) MAPK1HSD17B10ALDH1A1HPGDTDP1
SCHEMBL2432817 0.75 MTNR1B (0.43) L3MBTL1USP2ALOX15TSHRMAPK1
SCHEMBL1505131 0.75 RAB9A (0.54) L3MBTL1TSHRMAPK1HSD17B10RAB9A
SCHEMBL6042656 0.75 MTNR1A (0.68) L3MBTL1USP2ALOX15TSHRMAPK1
SCHEMBL6428728 0.74 CTSV (0.58) L3MBTL1RAB9AKDM4EALDH1A1FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2542529-B1 URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA LLC PHARMADIALL (RU) 2019-09-04 EP disclosed
US-9708265-B2 Urethanes, ureas, amidines and related inhibitors of factor Xa PHARMADIALL LIMITED LIABILITY COMPANY (RU) 2017-07-18 US disclosed
EP-2542529-A1 URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA Tovbin, Dmitry Gennadievich (RU) 2013-01-09 EP disclosed
US-20130005778-A1 URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA PHARMADIALL LIMITED LIABILITY COMPANY (RU) 2013-01-03 US disclosed
WO-2011108963-A1 URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA TOVBIN DMITRY GENNADIEVICH (RU) 2011-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005778-A1 URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA PLAUR, PLAU, UTS2R L3MBTL1 2694/4885USP2 139/4885ALOX15 1452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.